The estimated Net Worth of Jamie A Donadio is at least $453 Tisíc dollars as of 16 May 2019. Jamie Donadio owns over 7,500 units of Mirati Therapeutics Inc stock worth over $453,223 and over the last 10 years Jamie sold MRTX stock worth over $0.
Jamie has made over 4 trades of the Mirati Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Jamie exercised 7,500 units of MRTX stock worth $41,250 on 16 May 2019.
The largest trade Jamie's ever made was exercising 51,875 units of Mirati Therapeutics Inc stock on 1 March 2018 worth over $338,225. On average, Jamie trades about 5,641 units every 31 days since 2014. As of 16 May 2019 Jamie still owns at least 7,721 units of Mirati Therapeutics Inc stock.
You can see the complete history of Jamie Donadio stock trades at the bottom of the page.
Jamie's mailing address filed with the SEC is 9363 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... a Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: